It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A complex interaction of anabolic and catabolic metabolism underpins the ability of leukocytes to mount an immune response. Their capacity to respond to changing environments by metabolic reprogramming is crucial to effector function. However, current methods lack the ability to interrogate this network of metabolic pathways at single-cell level within a heterogeneous population. We present Met-Flow, a flow cytometry-based method capturing the metabolic state of immune cells by targeting key proteins and rate-limiting enzymes across multiple pathways. We demonstrate the ability to simultaneously measure divergent metabolic profiles and dynamic remodeling in human peripheral blood mononuclear cells. Using Met-Flow, we discovered that glucose restriction and metabolic remodeling drive the expansion of an inflammatory central memory T cell subset. This method captures the complex metabolic state of any cell as it relates to phenotype and function, leading to a greater understanding of the role of metabolic heterogeneity in immune responses.
Patricia Ahl et al. present Met-Flow, a flow cytometry-based approach for capturing the metabolic state of immune cells across multiple pathways. The authors apply Met-Flow to a central memory T cell subset, showing the importance of glucose restriction and metabolic reprogramming to T cell polarization and expansion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); National University of Singapore, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431)
2 Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); Agency for Science, Technology and Research, Tessa Therapeutics Pte Ltd, Institute of Molecular and Cell Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221)
3 Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221)
4 Agency for Science, Technology and Research, Institute of Molecular and Cell Biology, Singapore, Singapore (GRID:grid.185448.4) (ISNI:0000 0004 0637 0221); National University of Singapore, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, Singapore, Singapore (GRID:grid.4280.e) (ISNI:0000 0001 2180 6431); Baylor University, Institute of Biomedical Studies, Waco, USA (GRID:grid.252890.4) (ISNI:0000 0001 2111 2894)